Prime Medicine wins arbitration against Beam Therapeutics over PM647

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/6/2026

1. USO
2. CHRW
3. MRVL
4. AMD
5. RXO
6. OPCH
7. NVDA
8. LW
9. GOOGL
10. APLD

Go back to Prime Medicine wins arbitration against Beam Therapeutics over PM647

TD Cowen on Prime Medicine (PRME): 'We continue to view PRME as undervalued for the platform’s potential'

July 8, 2026 12:30 PM EDT

TD Cowen analyst Joseph Thome reiterated a Buy rating on Prime Medicine (NASDAQ: PRME).

The analyst comments "PRME announced a positive binding arbitration resolution with BEAM over PM647 in AATD, confirming PM647 is in PRMEs field with no monetary damages. This removes a key investor overhang and clears the path for a Q3:26 filing, with initial data in 2027. We continue to view PRME as undervalued for the platforms potential. Buy. PRME announced a positive, binding resolution of its previously disclosed arbitration with Beam Therapeutics, with the tribunal declaring that PM647 falls within PRMEs... More